SU SURAKSHA
Suraksha Diagnostic Q4 2026
SUSURAKSHA

Suraksha Diagnostic Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 22 May 2026

Management summary

  • Suraksha Diagnostic Limited concluded FY26 on a strong note with robust revenue growth of 23.1% YoY.
  • Network expansion and increased patient volumes..
  • While EBITDA margins saw a slight compression due to new center ramp-up, the company remains focused on operational efficiency and advanced diagnostic capabilities.
  • PAT margins declined due to higher depreciation, finance costs, and tax expenses, but management expects margin stabilization in FY27 as new centers mature.

Source: Inve concall analysis and management guidance record.

Highlights

  • Robust revenue growth: FY26 revenue from operations grew 23.1% YoY to INR3104.1 million, with Q4 FY26 revenue up 25% YoY to INR822 million.

  • Healthy EBITDA performance: FY26 blended EBITDA margin stood at 31.73%, and Q4 FY26 EBITDA increased 26% YoY to INR252 million.

  • Significant patient and test volumes: Served 1.37 million patients and performed 8.16 million clinical tests in FY26, with revenue per patient increasing to INR2,264.

  • Strategic network expansion: Expanded to 68 centers by March 26, including 2 new hub centers, 11 spoke centers, and 3 PPP centers, strengthening presence in Eastern India.

What they filed

Q4 FY26: revenue up 23.4%, net profit down 12.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue59 64 70 76 76 +29%79 +23%
EBITDA18 20 24 24 23 +28%24 +20%
Net profit6 8 10 9 8 +33%7 −12%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Margin

  • EBITDA Margin Margin · FY27 · High confidence 33%
  • EBITDA Margin Margin · mid-term · High confidence 35%

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
Pre-Ind AS EBITDA and PAT for FY26 Partial
Pre-Ind As EBITDA will be around INR75 crores and PAT will be INR53 crores.

Clarifies the company's financial performance under a different accounting standard, which can be important for comparative analysis.

Asked by Dhruv Maheshwari

Impact of elections on center openings Direct
Absolutely. Because of the election, some licenses and power was a little delayed. So out of the 4, 2 have already opened. And 2 are going to open this month.

Explains the reasons behind delays in network expansion, providing context for the pace of future growth.

Asked by Rajat Baldewa

Unlock risks & concerns, Q1 FY27 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 6 risks, concerns & management red flags
  • 5 watchlist triggers for Q1 FY27
  • +6 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image